Treatment of infantile hemangioma with topical β-blockers in pediatric practice: a review of the literature
DOI:
https://doi.org/10.15574/SP.2023.136.67Keywords:
infantile hemangioma, hemangioma treatment, local β-blockers, timololAbstract
The purpose of this review is to acquaint the audience with the benefits of infantile hemangioma (IH) treatment with local β-blockers, which are safe for the child, allow for the complete cure of hemangiomas without surgery, complications, scars, and cosmetic defects, and have practically no systemic side effects. We aimed to analyze the effectiveness and limitations of the use of local β-blockers, to show the possibility and expediency of IH management in pediatric practice, and to demonstrate that the goal of therapy is not the treatment of complications, but the prevention of their occurrence and complete resolution of the hemangioma without surgical intervention.
The use of topical β-blockers, such as timolol gel or solution, provides a non-surgical, non-invasive treatment option for IH, minimizing the systemic exposure and possible side effects associated with oral β-blockers. Local treatment is best started before the age of 2 months - at an early stage, when IHs are small in size, potentially preventing the need for more invasive treatment methods.
Topical use is associated with a lower risk of systemic side effects, such as hypotension or bradycardia, that can occur with oral β-blockers. Topical treatment can be applied at home, which can be more convenient for parents and caregivers, and also increases the opportunity for treatment and follow-up by pediatricians. In case of natural disasters or military operations, treatment can be done remotely using teledermatology.
The effectiveness of local β-blockers mostly depends on the age at which treatment was started: the earlier it was started, the higher the effectiveness. Treatment of complicated IH with deep soft tissue, mucosal, or airway involvement usually requires a combination of systemic propranolol and topical β-blockers or other interventions such as laser therapy.
The choice of treatment should be selected individually according to the degree of risk of IH, its size, localization, child's age, weight, and other parameters in each clinical case.
β-adrenoblockers are the most modern, effective, non-surgical, and safe method of treating IH, they can be used both for systemic and local application. IH can be successfully treated by pediatricians and dermatologists.
No conflict of interests was declared by the authors.
References
Almebayadh M. (2020). Successful treatment of ulcerated infantile IH with brimonidine-timolol cream: 2 cases report and review of the literature. J. Dermatolog. Treat. 31; 4: 433-434. https://doi.org/10.1080/09546634.2019.1603991; PMid:30973791
Anderson KR, Schoch JJ, Lohse CM et al. (2016). Increasing incidence of infantile IHs (IH) over the past 35 years: Correlation with decreasing gestational age at birth and birth weight. J. Am. Acad. Dermatol. 74; 1: 120-126. https://doi.org/10.1016/j.jaad.2015.08.024; PMid:26494585 PMCid:PMC4994883
Chakkittakandiyil A, Phillips R, Frieden U et al. (2012). Timolol maleate 0.5% or 0.1% gel-forming solution for infantile IHs: a retrospective, multicenter, cohort study. Pediatr. Dermatol. 29; 1: 28-31. https://doi.org/10.1111/j.1525-1470.2011.01664.x; PMid:22150436
Chan H, McKay C, Adams S, Wargon O. (2013). RCT of timolol maleate gel for superficial infantile IHs in 5- to 24-week-olds. Pediatrics. 31; 6: e1739-e1747. https://doi.org/10.1542/peds.2012-3828; PMid:23650294
Chang LC, Haggstrom AN, Drolet BA et al. (2008). Growth characteristics of infantile IHs: implications for management. Pediatrics. 122; 2: 360-367. https://doi.org/10.1542/peds.2007-2767; PMid:18676554
Cheng CE, Friedlander SF. (2016). Infantile IHs, complications, and treatments. Semin Cutan Med Surg. 35(3): 108-116. https://doi.org/10.12788/j.sder.2016.050; PMid:27607318
Gan LQ, Wang H, Ni SL, Tan CH. (2018) A prospective study of topical carteolol therapy in Chinese infants with superficial infantile IH. Pediatr. Dermatol. 35; 1: 121-125. https://doi.org/10.1111/pde.13361; PMid:29243341
Hagen R, Ghareeb E, Jalali O, Zinn Z. (2018). Infantile IHs: what have we learned from propranolol? Curr. Opin. Pediatr. 30; 4: 499-504. https://doi.org/10.1097/MOP.0000000000000650; PMid:29846253
Hogeling M, Adams S, Wargon O. (2011). A randomized controlled trial of propranolol for infantile IHs. Pediatrics. 128; 2: e259-e266. https://doi.org/10.1542/peds.2010-0029; PMid:21788220
Itinteang T, Brasch HD, Tan ST, Day DJ. (2011). Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for propranolol-induced accelerated involution. J. Plast. Reconstr. Aesthet. Surg. 64; 6: 759-765. https://doi.org/10.1016/j.bjps.2010.08.039; PMid:20870476
Itinteang T, Withers AH, Davis PF, Tan ST. (2014). Biology of infantile IH. Front Surg. 1; 38. https://doi.org/10.3389/fsurg.2014.00038; PMid:25593962 PMCid:PMC4286974
Ji Y, Chen S, Wang Q et al. (2018). Intolerable side effects during propranolol therapy for infantile IH: frequency, risk factors, and management. Sci Rep. 8(1): 4264. https://doi.org/10.1038/s41598-018-22787-8; PMid:29523832 PMCid:PMC5844887
Jong SDe, Itinteang T, Withers AH et al. (2016). Does hypoxia play a role in infantile IH? Arch. Dermatol. Res. 308; 4: 219-227. https://doi.org/10.1007/s00403-016-1635-x; PMid:26940670
Katona G, Csákányi Z, Gács E et al. (2012). Propranolol for infantile haemangioma: striking effect in the first weeks. Int. J. Pediatr. Otorhinolaryngol. 76; 12: 1746-1750. https://doi.org/10.1016/j.ijporl.2012.08.014; PMid:22944359
Kilcline C, Frieden IJ. (2008). Infantile IHs: how common are they? A systematic review of the medical literature. Pediatric Dermatology. 25; 2: 168-173. https://doi.org/10.1111/j.1525-1470.2008.00626.x; PMid:18429772
Kim JH, Lam JM. (2021). Pediatrics: how to manage infantile haemangioma. Drugs Context. 6; 10: 2020-12-6. https://doi.org/10.7573/dic.2020-12-6 PMid:33889196 PMCid:PMC8029639
Kovačević M, Lukinović Škudar V, Maričić G et al. (2014). Topical propranolol cream in the treatment of superficial infantile IHs: a literature review and 4 years of clinical experience. Acta Dermatovenero.l Alp. Pannonica Adriat. 23; 4: 75-78. https://doi.org/10.15570/actaapa.2014.18; PMid:25527040
Kurlak LO, Mistry HD, Cindrova-Davies T et al. (2016). The human placental renin-angiotensin system in normotensive and pre-eclamptic pregnancies at high altitude and after acute hypoxia-reoxygenation insult. J. Physiol. 594; 5: 1327-1340. https://doi.org/10.1113/JP271045; PMid:26574162 PMCid:PMC4771780
Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al. (2008). Propranolol for severe IHs of infancy. N. Engl. J. Med. 358; 24: 2649-2651. https://doi.org/10.1056/NEJMc0708819; PMid:18550886
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J et al. (2015). A randomized, controlled trial of oral propranolol in infantile IH. N. Engl. J. Med. 372; 8: 735-246.
Li G, Xu DP, Tong S et al. (2016). Oral propranolol with topical timolol maleate therapy for mixed infantile IHs in oral and maxillofacial regions. J. Craniofac. Surg. 27; 1: 56-60. https://doi.org/10.1097/SCS.0000000000002221; PMid:26716547
Lo K, Mihm M, Fay A. (2009). Current theories on the pathogenesis of infantile IH. Semin. Ophthalmol. 24; 3: 172-177. https://doi.org/10.1080/08820530902805438; PMid:19437354
Mashiah J, Kutz A, Rabia SH et al. (2017). Assessment of the effectiveness of topical propranolol 4% gel for infantile IHs. Int. J. Dermatol. 56; 2: 148-153. https://doi.org/10.1111/ijd.13517; PMid:28074521
Mulliken JB, Glowacki J. (1982). IHs and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast. Reconstr. Surg. 69; 3: 412-422. https://doi.org/10.1097/00006534-198203000-00003
Muñoz-Garza FZ, Ríos M, Roé-Crespo E et al. (2021). Efficacy and safety of topical timolol for the treatment of infantile IH in the early proliferative stage: A randomized clinical trial. JAMA Dermatol. 157; 5: 583-587. https://doi.org/10.1001/jamadermatol.2021.0596; PMid:33825828 PMCid:PMC8027942
Ng ZY, Kang GC, Chang CS, Por YC. (2016) Efficacy of topical timolol as primary monotherapy in cutaneous facial infantile IHs. J. Craniofac. Surg. 27; 6: e516-e520. https://doi.org/10.1097/SCS.0000000000002849; PMid:27428916
Oranje AP, Janmohamed SR, Madern GC, De Laat PC. (2011). Treatment of small superficial haemangioma with timolol 0.5% ophthalmic solution: a series of 20 cases. Dermatology. 223; 4: 330-334. https://doi.org/10.1159/000334778; PMid:22179543
Ovadia SA, Landy DC, Cohen ER et al. (2015). Local administration of β-blockers for infantile IHs: a systematic review and meta-analysis. Ann. Plast. Surg. 74; 2: 256-262. https://doi.org/10.1097/SAP.0000000000000390; PMid:25590249
Painter SL Hildebrand GD. (2016). Review of topical beta blockers as a treatment for infantile IHs. Surv. Ophthalmol. 61; 1: 51-58. https://doi.org/10.1016/j.survophthal.2015.08.006; PMid:26408055
Prasad A, Sinha AK, Kumar B et al. (2019). Individualized dosing of oral propranolol for treatment of infantile IH: a prospective study. Pan. Afr. Med. J. 32; 155.
Price A, Rai S, Mcleod RWJ et al. (2018). Topical propranolol for infantile haemangiomas: a systematic review. J. Eur. Acad. Dermatol. Venereol. 32; 12: 2083-2089. https://doi.org/10.1111/jdv.14963; PMid:29569772
Püttgen K, Lucky A, Adams D. (2016). Topical timolol maleate treatment of infantile IHs. Pediatrics. 138 (3): e20160355. https://doi.org/10.1542/peds.2016-0355; PMid:27527799
Ritter MR, Butschek RA, Friedlander M, Friedlander SF. (2007). Pathogenesis of infantile haemangioma: new molecular and cellular insights. Expert Rev. Mol. Med. 9; 32: 1-19. https://doi.org/10.1017/S146239940700052X; PMid:18045510
Smith CJF, Friedlander SF, Guma M, et al. (2017). Infantile IHs: An updated review on risk factors, pathogenesis, and treatment. Birth Defects Res. 109; 11: 809-815. https://doi.org/10.1002/bdr2.1023; PMid:28402073 PMCid:PMC5839165
Tan ST, Itinteang T, Day DJ et al. (2012). Treatment of infantile haemangioma with captopril. Br. J. Dermatol. 167; 3: 619-624. https://doi.org/10.1111/j.1365-2133.2012.11016.x; PMid:22533490
Tang YJ, Zhang ZZ, Chen SQ et al. (2015). Effect of topical propranolol gel on plasma renin, angiotensin II, and vascular endothelial growth factor in superficial infantile IHs. J. Huazhong Univ. Sci. Technolog. Med. Sci. 35; 5: 759-762. https://doi.org/10.1007/s11596-015-1503-5; PMid:26489635
Weibel L, Barysch MJ, Scheer HA et al. (2016). Topical timolol for infantile IHs: evidence for efficacy and degree of systemic absorption. Pediatr. Dermatol. 33; 2: 184-190. https://doi.org/10.1111/pde.12767; PMid:26840644
Wu HW, Wang X, Zhang L et al. (2018). Topical timolol vs. oral propranolol for the treatment of superficial infantile IHs. Front Oncol. 8: 605. https://doi.org/10.3389/fonc.2018.00605; PMid:30619747 PMCid:PMC6305365
Xu DP, Cao RY, Tong S et al. (2015). Topical timolol maleate for superficial infantile IHs: an observational study. J. Oral. Maxillofac. Surg. 73; 6: 1089-1094. https://doi.org/10.1016/j.joms.2014.12.026; PMid:25843815
Xu G, Lv R, Zhao Z, Huo R. (2012). Topical propranolol for treatment of superficial infantile IHs. J. Am. Acad. Dermatol. 67; 6: 1210-1213. https://doi.org/10.1016/j.jaad.2012.03.009; PMid:22516113
Yilmaz L, Dangoisse C, Semaille P. (2013). Infantile IH and propranolol: a therapeutic "revolution". Literature review. Rev. Med. Brux. 34; 6: 479-784.
Zhai YN, Song HT, Chen SQ, et al. (2013) Effect of propranolol gel on infantile IHs. Zhonghua Zheng Xing Wai Ke Za Zhi. 29; 1: 25-28.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
